Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 136

Title: Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation

Reviewer code: 00004187

Science editor: Zhai, Huan-Huan

Date sent for review: 2012-08-21 08:42

Date reviewed: 2012-12-14 06:27

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[ ] Grade A: Priority Publishing	Google Search:	[ ] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[Y] Grade C (Good)	[Y] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ] Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[ ] Minor revision
		[ ] No records	[Y] Major revision

COMMENTS TO AUTHORS

The work is interesting and original. - The abstract should be easier (Material and methods, and results). - These tumors should have made loss of protein expression and microsatellite instability (MSI testing and immunostaining for MLH1, MSH2, MSH6, and PMS2 proteins.)   - Why not study the degree of methylation   with 5 markers (CACNAG1, SOCS1, RUNX3, NEUROG1, and MLH1)? tumors with the CpG island methylator phenotype (CIMP) - Remove the phrase "Microsoft Office Excel 2007,,," - This article should revise one skilled in quantitative PCR assay. - It is understood that the expression of LATS1 Dukes B is lower than in Duke's stage C or D. - Why not study results by the TNM classification? - All P less than 0.05 should be equal, for example P = 0.00003 (P<0.05) - Discuss: What are the clinical implications of the study? Can apply blood? Are they related to treatment response?